NP mentioned reducing fibrosis in trials. Whether he was talking about Cytodyn's preclinical trials or maraviroc's trials. I believe leronlimab's effect on inflammation is greater than maraviroc so our results should be superior.

maraviroc studies -
https://www.ncbi.nlm.nih.gov/pubmed/25394147?dopt=Abstract